The UK’s Competition and Markets Authority (CMA) has consulted on a £23m ($29m) offer from Vifor Pharma in relation to the CMA’s investigation into the company’s conduct in the market for the supply of high-dose intravenous iron to the NHS. The offer is part of a wider set of
Free Trial
Register for free to keep reading.
To continue reading this article and unlock full access to GRIP, register now. You’ll enjoy free access to all content until our subscription service launches in early 2026.
- Unlimited access to industry insights
- Stay on top of key rules and regulatory changes with our Rules Navigator
- Ad-free experience with no distractions
- Weekly podcasts from trusted external experts
- Fresh compliance and regulatory content every day
